Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Cambrex Corporation    CBM

Delayed Quote. Delayed  - 09/23 10:02:00 pm
46.6 USD   +0.65%
09/09 CAMBREX : Advantages of Integrating Biocatalytic Transformations int..
09/08 CAMBREX : Advantages of Integrating Biocatalytic Transformations int..
09/07 CAMBREX : Announces Investment and Expansion to Large Scale, Multi-P..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/19/2016 09/20/2016 09/21/2016 09/22/2016 09/23/2016 Date
46.04(c) 45.99(c) 46.77(c) 46.3(c) 46.6(c) Last
265 560 243 033 184 866 382 063 394 996 Volume
-0.20% -0.11% +1.70% -1.00% +0.65% Change
More quotes
Financials ($)
Sales 2016 483 M
EBIT 2016 120 M
Net income 2016 79,8 M
Debt 2016 -
Yield 2016 -
Sales 2017 531 M
EBIT 2017 136 M
Net income 2017 90,9 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 19,18
P/E ratio 2017 16,95
Capi. / Sales2016 3,10x
Capi. / Sales2017 2,82x
Capitalization 1 498 M
More Financials
Company
Cambrex Corp. engages in the provisio ofproducts, services and technologies to accelerate and improve the development and commercialization of new and generic therapeutics.It supplies its products and services to innovator and generic pharmaceutical companies.Its products include generic and... 
Sector
Pharmaceuticals
Calendar
11/01Earnings Release
More about the company
Surperformance© ratings of Cambrex Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CAMBREX CORPORATION
09/09 CAMBREX : Advantages of Integrating Biocatalytic Transformations into Small Mole..
09/08 CAMBREX : Advantages of Integrating Biocatalytic Transformations into Small Mole..
09/07 CAMBREX : Announces Investment and Expansion to Large Scale, Multi-Purpose Manuf..
09/06 Cambrex Announces Investment and Expansion to Large Scale, Multi-Purpose Manu..
08/26 Cambrex to Present at Upcoming Investor Conferences in September
07/28 CAMBREX : posts 2Q profit
07/28 CAMBREX CORP : Results of Operations and Financial Condition, Financial Statemen..
07/28 CAMBREX : Management's Discussion and Analysis of Financial Condition and Result..
07/28 Cambrex Reports Second Quarter 2016 Financial Results
07/26 Cambrex to Announce Second Quarter 2016 Financial Results on July 28, 2016
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/31 SHORT CAMBREX : The Biggest Loser In Gilead's Hepatitis C Sales Downturn
08/01 BIOTECH FORUM DAILY DIGEST : The Rally Continues, Finally Some Good News For Ion..
07/31 Cambrex's (CBM) CEO Steven Klosk on Q2 2016 Results - Earnings Call Transcrip..
07/28 Cambrex beats by $0.09, beats on revenue
07/27 Notable earnings before Thursday?s open
Advertisement
Chart CAMBREX CORPORATION
Duration : Period :
Cambrex Corporation Technical Analysis Chart | CBM | US1320111073 | 4-Traders
Full-screen chart
Technical analysis trends CAMBREX CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 55,4 $
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Steven M. Klosk President, Chief Executive Officer & Director
Shlomo Yanai Non-Executive Chairman
Shawn P. Cavanagh Chief Operating Officer & Executive Vice President
Gregory P. Sargen Chief Financial Officer & Executive Vice President
Peter G. Tombros Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CAMBREX CORPORATION-1.04%1 498
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results